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Significant improvement in the management of breast carcinoma
has been achieved over the last few decades, mostly because of the
use of combinations of surgery, radiotherapy and chemoendocrine
therapy (Powles et al, 1995; Fisher et al, 1997). Adjuvant and
neoadjuvant chemotherapy is delivered with the intention of
controlling micrometastases. The 20-year follow-up of the first
combination chemotherapy regimen reported by Bonadonna et al
(1995) involved cyclophosphamide, methotrexate and 5-fluoro-
uracil. Various other combinations have been tried, and use of
anthracyclines is reported to improve the results (Brincker et al,
1983); mitoxantrone has been tried in place of doxorubicin and
may have fewer side-effects (Powles et al, 1991).
A number of chemotherapy drugs, especially alkylating agents
and some anthracyclines used in breast cancer treatment, are asso-
ciated with increased risk of secondary acute myeloid leukaemia
(sAML) or myelodysplasia (MDS), (Pedersen-Bjergaard and
Rowley, 1994). This analysis was undertaken in breast cancer
patients to ascertain whether there is a similar risk of secondary
AML/MDS associated with mitoxantrone.
PATIENTS AND METHODS
The prospectively maintained database at the Royal Marsden
Hospital was used to identify patients with breast carcinoma
treated with mitoxantrone-based regimens in the period
1984–1995. Patients who developed leukaemia or MDS were
identified in the Royal Marsden Hospital database and also by
accessing data reported to the Thames Cancer Registry. Details
from these sources were cross-checked and found to be consistent.
Chemotherapy regimens
From 1984–1992, 1282 patients received MMM (mitoxantrone 
7 mg m–2 every 3 weeks, methotrexate 35 mg m–2 every 3 weeks,
mitomycin C 7 mg m–2 every 6 weeks). From 1992 onwards
mitomycin was excluded from the regimen since there was an
increased incidence of haemolytic-uraemic syndrome (Montes et
al, 1993), and the subsequent 492 patients were treated (in
1992–1995) with MM (methotrexate 35 mg m–2 every 3 weeks,
and mitoxantrone 11 mg m–2 every 3 weeks). Patients also
received local radiotherapy to the chest wall, and tamoxifen 20 mg
daily. Table 1 summarizes treatments and characteristics of
patients in the MMM and MM groups.
Diagnosis of MDS/AML
MDS/AML was diagnosed using French-American-British (FAB)
criteria (Bennett et al, 1982; 1985). Cytogenetic analysis was
performed using conventional methods.
Statistical methods
Patients were considered to be at risk of developing MDS/AML
from the initial date of treatment with MMM or MM until the last
follow-up or death. The actuarial incidence was calculated by the
life-table method of Kaplan and Meier (1958). A comparison of
patients treated with MMM and MM was carried out using the
Logrank test. Survival after diagnosis of MDS/AML was also
ascertained by the life-table method.
The expected numbers of acute myeloid leukaemias and
myelodysplastic syndromes in an age/sex matched population
were calculated by applying the age- and sex-specific figures for
leukaemias in England and Wales (supplied by the Office of
Population Census and Surveys) assuming a Poisson distribution
to the person-years at risk. The age-specific incidence figures for
MDS were obtained from the data published by Williamson et al
(1994). The relative risk of developing AML/MDS was calculated
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RESULTS
In the period 1984–1995 1774 patients received MMM
chemotherapy (n = 1282, median age 54 years, range 20–90) or
MM (n = 492, median age 54 years, range 27–83) in adjuvant or
neoadjuvant setting. Median follow-up was 5 years.
Five patients developed AML and four developed MDS after
treatment with MTZ-based chemotherapy, giving an incidence of
15 per 100 000 years follow-up. The median age was 60 years
(range 45–68). Details of the cases of MDS and AML are shown in
Table 2. On average, MDS/AML developed 2.5 years (range
1.3–7) following MTZ-based chemotherapy (Table 2). There was
no difference in incidence between prior MM or MMM
chemotherapy (3/492 versus 6/1282; P = 0.9). The risk of devel-
oping MDS/AML at 5 and 10 years was calculated as 1.1% (95%
CI: 0.6–2.2%) and 1.6% (95% CI: 0.7–3.6%) respectively (Figure
1). The relative risk of developing MDS/AML was 10.1 times
greater than in an age- and sex-matched normal population (95%
CI: 3.5–16.7). For MDS alone the risk was 8.6 times greater, and
for leukaemia alone it was 14.1 times greater than in the normal
population (Table 3).
Women with AML/MDS had received the following total drug
doses: Mitoxantrone 80 mg (range 60–162 mg), methotrexate 
310 mg (range 265–400 mg), in six cases with mitomycin 45 mg
(range 39–51 mg). In addition to MTZ-based chemotherapy, all
patients had surgery and additional chest wall irradiation, while
five patients in this group had adjuvant therapy with tamoxifen.
An abnormal cytogenetic clone was present in eight cases, while
one patient had no clonal abnormality. Five individuals had
abnormalities involving chromosomes 5 and/or 7, and three had
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Table 1 Patients treated with MM/MMM
MMM MM
Number of patients 1282 492
Male/Female 5/1277 1/491
Age (median (range)) 54 (20–90) 54 (27–83)
Local RT 366 319
No RT 214 84
RT (no information)a 702 89
Number of courses 6 6
(median (range)) (1–15) (1–11)
a RT (local radiotherapy) data not available before April 1988
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Figure 1 Incidence of MDS/AML after MZT-based chemotherapy.
Table 2 Details of secondary MDS/AML patients
Case Age Diagnosis Ca. Breast Regimen Time to Total chemotherapy dosesd Cytogenetics Outcome
(years) T/Ta AML/MDS (months)
(years) Mitoxantrone Methotrexate Mitomycin
A 64 AML M7 S, CT+RT, MMM 3.6 68 mg 270 mg 39 mg 45, XX, –7 Dead
Tamox (46.9) (186.2) (26.9) 2
B 50 AML M1 S, CT+RT MMM 4.2 60 mg 300 mg 45 mg 47, XX, +mar Dead
(37.5) (187.5) (28.1) 1
C 71 MDS/RA CT, S, MMM 3.2 79 mg 310 mg 45 mg 46, XX Dead
CT+RT, (45.1) (177.1) (25.7) 10
Tamox
D 46 AML M2 CT, S, MM 1.3 162 mg 400 mg nil 46, XX, t(8;21)(q22;q22) In CR1
CT+RT (93.1) (229.9) 60
E 75 MDS HADc, S, MM 2.5 96 mg 320 mg nil 46, XX, del(1)(p32p34), Dead
Hypoplas HAD+RT FECb (59.6) (198.8) del(5)(q13q33), 17
der(7)t(7;12)(q3;q13),
der(12)t(7;12)(q22;q13)
F 58 AML M3 CT, S, CT, MM 1.8 126 mg 300 mg nil 46, XX, t(1;2)(p22;q21), In CR1
RT, Tamox (70) (166.7) t(15;17)(q22;q21) 18
G 66 MDS CT, S, CT, MMM 2.4 77 mg 265 mg 50 mg 45, XX, del(3)(p12),–7, Dead
RARS RT, Tamox (38.5) (132.5) (25) –9 add(17)(p1), –8, +mars/ 8
45, XX, idem, del(5)(q3)
H 62 MDS S, RT, MMM 7 93 mg 320 mg 51 mg 46, XX, –7, +mar Alive
Tamox (51.7) (177.8) (28.3) 12
I 77 AML M2 S, RT, MMM 2.4 80 mg 400 mng 40 mg 45, XX, add(5)(q15), der(11) Dead
Tamox, (53.3) (260.6) (26.6) add(11)(p15)add(11)(q23), 27days
VAC/VEC –18, del(20)(q13)
a S = surgery, CT = chemotherapy, RT = radiotherapy; bFEC-5FU, epirubicin, cyclophosphamide, VAC/VEC = vincristine, adriamycin (epirubicin),
cyclophosphamide, Tamox = tamoxifen; cHAD-hydroxyandrostenedione; dTotal dose in mg, mg m–2 in parenthesescomplex abnormalities. Other chromosome abnormalities included
t(8;21), t(15;17) with t(1;2), and one patient had an unidentified
additional abnormality (Table 2).
Patient outcomes are shown in Table 2. All five patients with
AML were treated with chemotherapy. Two are alive, and three
died of chemotherapy-related problems. Four patients with MDS
were over 60 years-of-age and were managed with supportive care
alone; three have died. In one patient the MDS evolved into AML.
DISCUSSION
There has been significant improvement in survival and cure
expectancy for patients with breast cancer due to combined
modality treatment using surgery, chemotherapy and radiation.
Selection of the optimum form of combination chemotherapy for
breast cancer should take into account associated long-term risks.
The CMF regimen is a standard regimen for adjuvant treatment
and its long-term benefit has been established. However, there is a
potential risk of secondary leukaemia associated with most of
these drugs (Henderson et al, 1990).
Aul et al (1992) have shown that the risk of developing
MDS/AML increases with age; the average annual incidence in all
age-groups in the period 1986–1990 was 4.11 per 100 000 per
year, with a considerable rise of incidence in the older population.
The average incidence in the population > 70 years-of-age was
22.81 per 100 000 per year (33.88 for men and 18.02 for women),
while the incidence of AML is 6.7 per 100 000 per year. Another
study has confirmed an increased incidence of MDS in older
patients (Williamson et al, 1994).
We assessed the incidence of MDS and AML occurring in a
cohort of patients with breast cancer treated with mitoxantrone-
containing regimens. The current report is one of the largest
analyzing risk of secondary acute myeloid leukaemia after mitox-
antrone in breast cancer patients. With a median follow-up of 5
years, there were nine cases of AML/MDS among 1774 patients
giving a crude incidence of 15 per 100 000 years of follow-up.
Bonadonna et al (1993) noticed a cumulative risk of 0.23% +/–
0.15% at 15 years, and a relative risk 2.3 ´ greater compared to the
normal population after a median follow-up of 12 years in patients
receiving CMF. However, the Eastern Cooperative Oncology
Group (ECOG) found a crude incidence rate of 26 per 100 000
years of follow-up for a secondary haematological malignancy
after treatment with standard adjuvant chemotherapy, which with
standard dose cyclophosphamide was not much higher than that
seen in the general population (Tallman et al, 1995).
To improve tumour response rates and prolong survival, anthra-
cycline-based regimens have been introduced, with results at least
as good as those seen with CMF. However, the risk of secondary
AML with doxorubicin-containing regimens has been found to be
1.5% (0.7–2.9%) at 10 years (Diamandidou et al, 1996) and the
risk was significantly higher after chemoradiotherapy than after
chemotherapy alone (10 year actuarial risk of 2.5% vs 0.5%).
Mitoxantrone may be less toxic and has also been used more
recently in combination chemotherapy for breast cancer (Powles et
al, 1991).
To our knowledge there is no association between mitomycin
and methotrexate and hematological malignancies (Rustin et al,
1996), and there are few reports concerning a possible leukae-
mogenic effect of mitoxantrone (Philpott et al, 1993; Mitchell et
al, 1996). Therapy-related or secondary leukaemias often show
cytogenetic abnormalities, and there are characteristic differences
which may be specific for particular chemotherapy agents; alkyl-
ating agents are associated with abnormalities of chromosomes 5
and 7 while topoisomerase-II inhibitors are associated with chro-
mosome 11 abnormalities. (Ellis et al 1993; Smith et al, 1996).
In our study, 67% of patients had predominantly unbalanced
chromosome aberrations that are associated with prior radio-
therapy and/or alkylating agent treatment, but not with mitox-
antrone therapy. However, all the patients with MDS/AML had
also received radiotherapy and hence it is possible that in our
patients the risk of MDS/AML was more likely to be associated
with the combination of chemotherapy and radiotherapy
(Johansson et al, 1996).
Two patients in this series who had balanced translocations had
a family history of cancer. One had a sister with brain cancer,
while the other had a mother with lung cancer and a sister with
breast cancer. Because of their family backgrounds, these patients
may be in a high-risk category and more prone to developing a
secondary malignancy; MDS/AML in this situation is more likely
to represent a second primary rather than a secondary haematolog-
ical malignancy (Thirman and Larson, 1996). An increased family
incidence of haematological malignancies in these cases may also
indicate a role for oncogenes and tumour suppressor genes in the
development of MDS/AML (Skuse and Ludlow, 1995).
CONCLUSION
Our study has shown an increased incidence of MDS and AML
after MTZ-based chemotherapy, compared to that seen in the
general population. However, it is difficult to estimate how much
of this is due to the MTZ-based chemotherapy rather than to the
population being at higher risk because of family history, age or
additional treatment with chemo/radiotherapy.
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